Stockscreener 앱 받기
119.63
0.59%
0.70
시간 외 거래:
119.50
-0.13
-0.11%
전일 마감가:
$118.93
열려 있는:
$119.285
하루 거래량:
8.32M
Relative Volume:
0.71
시가총액:
$295.77B
수익:
$64.93B
순이익/손실:
$18.26B
주가수익비율:
16.44
EPS:
7.2751
순현금흐름:
$12.36B
1주 성능:
+4.77%
1개월 성능:
-3.38%
6개월 성능:
+52.28%
1년 성능:
+36.56%
1일 변동 폭
$118.60
$121.07
1주일 범위
$114.02
$121.07
52주 변동 폭
$73.31
$125.14
머크앤드컴퍼니 Stock (MRK) Company Profile
명칭
Merck Co Inc
전화
908-740-4000
주소
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, AZN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
119.63 | 294.04B | 64.93B | 18.26B | 12.36B | 7.2751 |
LLY
Lilly Eli Co
|
878.24 | 801.34B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.45 | 576.24B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
209.40 | 373.42B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
188.42 | 284.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
머크앤드컴퍼니 Stock (MRK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-02-13 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2026-01-08 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-12-18 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-11-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-10-13 | 재개 | Citigroup | Neutral |
| 2025-09-17 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-02-18 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-02-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-01-08 | 다운그레이드 | Truist | Buy → Hold |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-12-04 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-11 | 다운그레이드 | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-03-11 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2024-01-04 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Buy |
| 2023-10-27 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Hold |
| 2023-04-13 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-03-28 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2023-03-13 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 개시 | Jefferies | Buy |
| 2023-02-22 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-10-10 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-14 | 업그레이드 | Berenberg | Hold → Buy |
| 2022-07-06 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 재개 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-16 | 개시 | Daiwa Securities | Neutral |
| 2021-12-13 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-12-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-29 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-01 | 업그레이드 | Argus | Hold → Buy |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-08-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-06-12 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-16 | 개시 | SVB Leerink | Outperform |
| 2019-07-03 | 개시 | Mizuho | Buy |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-05-13 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 재확인 | Citigroup | Buy |
| 2018-10-09 | 재개 | Guggenheim | Buy |
| 2018-04-23 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-04-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-03-12 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-07 | 재확인 | Morgan Stanley | Equal-Weight |
| 2018-01-16 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
머크앤드컴퍼니 주식(MRK)의 최신 뉴스
Jim Cramer on Merck & Co.: “If We’re Really Going Into an Oil Shock-Induced Slowdown, I Think This One’s Likely an Outperformer”” - insidermonkey.com
Dilution adjustment of Merck & Co., Inc. – BSESOF:6MK - TradingView
[SCHEDULE 13G/A] Merck & Co., Inc. Amended Passive Investment Disclosure - Stock Titan
Mizuho downgrades Terns Pharmaceuticals stock rating on Merck deal - Investing.com
Merck Agrees to Acquire Terns for $6.7B - Contract Pharma
Can MRK's Ongoing M&A Push Aid Long-Term Growth Ahead of Keytruda LOE? - TradingView
Merck Stock Soars 50% in 6 Months: Buy, Hold, or Take Profits? - TradingView
Global X Japan Co. Ltd. Takes Position in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Synergy Asset Management LLC - MarketBeat
Parsons Capital Management Inc. RI Sells 14,477 Shares of Merck & Co., Inc. $MRK - MarketBeat
Brucellosis Vaccines Market is Going to Booming Growth 2026 With - openPR.com
Animal Vaccines Market Set to Boom Rapidly by 2033 | Merck & Co., - openPR.com
Dakota Wealth Management Has $19.04 Million Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Acquired by Fort Washington Investment Advisors Inc. OH - MarketBeat
Merck & Co., Inc. stock: Strategic acquisitions and oncology focus position shares for long-term val - ad-hoc-news.de
RBC Reiterates Merck (MRK) Outperform, Notes Investor Concerns Over “Modest Premium” - insidermonkey.com
Merck’s deal for Terns sparks debate over a possible biotech bidding war - biopharmadive.com
Investors heavily search Merck & Co., Inc. (MRK): Here is what you need to know - MSN
Merck to Boost Oncology Pipeline With $6.7B Terns Buyout, Stock Up - TradingView
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know - Yahoo Finance
A $6.7 Billion Blockbuster Deal: Merck Bets on the CML Opportunity - Moomoo
Guggenheim reiterates Merck stock rating on Terns acquisition - Investing.com
SeaCrest Wealth Management LLC Buys 11,454 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck (MRK) Stock; Edges Higher as $6.7B Terns Acquisition Boosts Cancer Pipeline Outlook - MEXC
Merck expands haematology pipeline with $6.7bn acquisition of Terns Pharmaceuticals - European Pharmaceutical Review
Ferguson Wellman Capital Management Inc. Grows Stake in Merck & Co., Inc. $MRK - MarketBeat
Czech National Bank Raises Stock Position in Merck & Co., Inc. $MRK - MarketBeat
Merck to purchase oncology company - The Arkansas Democrat-Gazette
Merck & Co. Inc. stock surges on Terns Pharmaceuticals acquisition and Dow Jones momentum amid marke - AD HOC NEWS
Bank of America Securities Reduces PT on Merck & Co., Inc. (MRK), Keeps a Buy Rating - MSN
Market Today: Meta/Google verdict, Arm chip, Merck-Terns deal - GuruFocus
Merck (TERN) plans tender offer to acquire Terns under March 24, 2025 merger - Stock Titan
If You Invested $1,000 in Merck & Co (MRK) - Stock Titan
Merck to Buy Terns for $6.7B to Grow in Blood Cancers - marketscreener.com
Sherwin-Williams Co., Merck share gains lead Dow's nearly 300-point jump - MSN
Merck's Deal For Terns And Its Stellar CML Drug Candidate Looks Like Good Business (MRK) - Seeking Alpha
Market movers: Sarepta Therapeutics, Chewy, Merck, Cognyte Software… - Proactive financial news
Merck's $6.7B Acquisition of Tern Pharmaceuticals Raises Investo - gurufocus.com
Merck (NYSE:MRK) Innovation Strategy Drives S&P 500 ETF Alignment - Kalkine Media
Pharma giant Merck to acquire Terns Pharmaceuticals for $6.7 billion - marketscreener.com
Merck’s $6.7B Terns Acquisition Positions It to Challenge a Blockbuster Novartis Cancer Drug - MedCity News
Dow's 414-Point Rally Highlighted By Gains In Merck, Amazon.Com Inc. Stocks - Moomoo
Merck announces another pricy purchase ahead of Keytruda deadline - WFMZ.com
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B (XLV:NYSEARCA) - Seeking Alpha
Merck (MRK) Faces Mixed Reactions Following Terns Acquisition An - gurufocus.com
From failure to hit to a $6.7 billion buyout: Terns Pharma gets big offer from Merck - The Business Journals
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst - Benzinga
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst - Benzinga
NVIDIA Corp., Merck Share Gains Contribute To Dow's Nearly 300-Point Jump - Moomoo
Terns Pharmaceuticals jumps after Merck agrees to acquire it for $53 per share in cash - Quiver Quantitative
Merck bids $6.7 billion for Terns Pharmaceuticals - The Pharma Letter
머크앤드컴퍼니 (MRK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.74%
1.02%
자본화:
|
볼륨(24시간):